BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Beats Estimates By $0.06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06, Briefing.com reports. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the previous year, the business posted ($0.28) EPS. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $5.10 on Thursday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.96. The firm has a 50-day moving average price of $4.89 and a two-hundred day moving average price of $5.45. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -4.77 and a beta of 1.96.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.00.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.